Related Experiment Video
Updated: Feb 10, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?
S G Berntsson1, A Kristoffersson1,2, I Boström3
1Department of Neuroscience, Neurology, Uppsala University, University Hospital, Uppsala, Sweden.
Objectives:
Off-label use of rituximab to treat MS patients in Sweden is high, and the need for long-term safety data may not be met. Our objectives were to assess the rate of rituximab prescription in patients with multiple sclerosis in Sweden and, in addition, to evaluate the safety of rituximab in a single centre for patients with multiple sclerosis.
Material And Methods:
Review of the Swedish MS register was performed to study the number of MS patients treated with rituximab during the last 6 years. Investigation also included a retrospective review of medical files in search for possible side effects/adverse events in all adult patients with MS treated with rituximab at Uppsala University Hospital.
Results:
Presently, in Sweden the rate of rituximab prescriptions in relation to other annually started of disease- modifying drugs in MS is 53.5%.
Conclusions:
The share of MS patients in Sweden who are treated with rituximab is very high, and also rapidly increasing. Taken into account the off-label use, cases with adverse medical conditions that could possibly be related to rituximab use should be reported thoroughly.
Related Concept Videos
What Are Outliers?
The z score is used to find outliers or unusual values. It should be noted that any values beyond -2 and +2 are...
Outliers and Influential Points
Quantifying and Rejecting Outliers: The Grubbs Test
Increasing Function
Increased Body Temperature
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...

